H.C. Wainwright raised the firm’s price target on Halozyme to $65 from $50 and keeps a Buy rating on the shares after the company was granted a new European Union patent that extends the protection of its proprietary Enhanze technology through March 6, 2029. While this patent life extension does not provide an immediate benefit to most of the royalty streams in the Halozyme portfolio, it provides a key extension of the intellectual property protecting Darzalex in the EU, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HALO:
- Halozyme Raises Full Year 2024 Financial Guidance and Updates 5-Year Financial Outlook
- Halozyme granted European patent covering ENHANZE drug delivery platform
- Halozyme and Bristol Myers’ combination receives updated FDA action date
- Halozyme price target raised to $45 from $39 at Leerink
- Halozyme price target lowered to $71 from $72 at JMP Securities